A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery

Inclusion Criteria: * Be male or female 18 years of age and above * Presence of visually significant cataracts in both eyes * Have a chief complaint consistent with visually significant cataracts * Be able to communicate effectively with the study personnel and be able to understand and follow directions * Be medically fit with clinically acceptable laboratory profiles and ECG * Be willing to carry out the required pre op directions and post op care and be able to make the scheduled appointment * Have given the written informed consent for participation in the study * In addition, female patients of child bearing potential age must have a negative urine pregnancy test Exclusion Criteria: * Participation in any ophthalmic indicative bioavailability/ bioequivalence/ Pharmacokinetic study or received an ophthalmic indicative investigational drug within a period of three months prior to screening * Presence or history of recent viral corneal disorder or active corneal condition which is contraindicated. * Presence or history of uveitis or uveitis * Presence of retinal disorders * Ocular trauma within three months of the trial * Patients who had received topical and or systemic/ oral steroids * Uncontrolled diabetes * History of any allergies * Known hypersensitivity or allergy to TobraDex® in combination or its components * Clinical laboratory test values outside the acceptable reference range and when confirmed on re-examination deemed to be clinically significant as determined by the investigator(s) * Clinically significant illness during 3 weeks prior to Visit 1 (as determined by the investigators) * Presence of a clinically significant systemic disorder